Search

John Andrew Ziemniak

from Pottstown, PA
Age ~69
Get Report
Also known as:
John A Ziemniak, John K
Related to:
Marie Tokasz Ziemniak, 66David S Udis, 66Lewis Udis, 87Stuart Udis, 38Carol Udis, 65Brett Udis, 35
Connected to:
Laurie L Ziemnik, 60Ann F Ziems, 105April C Ziems, 70Katherine L Ziems, 64Lee J Ziemski, 51Marci L Ziemski, 63Mike Ziemski, 38Matthew T Zien, 34Gretchen M Zience, 75Richard P Ziencina, 77

John Ziemniak Phones & Addresses

  • Pottstown, PA
  • Ambler, PA
  • Havertown, PA
  • Gwynedd Valley, PA
  • Havertown, PA

Work

Company: John ziemniak ph.d Jan 2000 Position: Biography

Industries

Pharmaceuticals

Resumes

Resumes

John Ziemniak Photo 1

Biography

View page
Location:
1010 Larchmont Ave, Havertown, PA
Industry:
Pharmaceuticals
Work:
John Ziemniak Ph.d
Biography
Gwynedd Pharmaceutical Consultants
Co-Founder and Partner

Business Records

Name / Title
Company / Classification
Phones & Addresses
John Ziemniak
Vice-President
Gwynedd Pharmaceutical Consults Inc
Dentist's Office
715 Evans Rd, Gwynedd Valley, PA 19437
PO Box 472, Gwynedd Valley, PA 19437

Publications

Us Patents

Pharmaceutical Preparations For Treatments Of Diseases And Disorders Of The Breast

View page
US Patent:
7812010, Oct 12, 2010
Filed:
Jan 2, 2004
Appl. No.:
10/751056
Inventors:
Gerianne T. DiPiano - Malvern PA, US
Peter Kevin Mays - Philadelphia PA, US
John Ziemniak - Gwynedd Valley PA, US
Assignee:
Femmepharma, Inc. - Wayne PA
International Classification:
A61K 31/56
A61K 9/00
A61K 9/14
US Classification:
514171, 514169, 424401, 424400, 424484
Abstract:
Formulations for topical or local administration of drugs directly to the breast or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the breast, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in the region to be treated with a reduction of side effects compared to those administered systemically. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion or foam.

Transvaginal Delivery Of Drugs

View page
US Patent:
20110003000, Jan 6, 2011
Filed:
Jul 6, 2009
Appl. No.:
12/497865
Inventors:
Gerianne Tringali DiPiano - Malvern PA, US
Thomas I. Janicki - Shaker Heights OH, US
Peter Kevin Mays - Philadelphia PA, US
John Andrew Ziemniak - Gwynedd Valley PA, US
International Classification:
A61K 9/14
A61K 9/12
A61K 31/56
A61K 31/24
A61P 13/00
A61P 15/02
US Classification:
424489, 424 45, 514169, 514534
Abstract:
Drug delivery compositions which are suitable for transvaginal administration for the treatment of diseases and disorders of the urogenital tract are described. The drug delivery compositions are administered directly to the vagina using a convenient transvaginal application that deposits a very small volume of drug at the desired site for delivery. This method of administration reduces the systemic levels of the drugs and decreases the side effects which are associated with systemic administration. In the preferred embodiment, the compositions are in the form of a gel. The formulation is administered in volumes of less than or equal to 1 milliliter. In the preferred embodiment, the composition contains an antimuscarinc drug, such as oxybutynin.

Pharmaceutical Preparations For Treatments Of Diseases And Disorders Of The Breast

View page
US Patent:
20110212934, Sep 1, 2011
Filed:
Aug 30, 2010
Appl. No.:
12/871678
Inventors:
Gerianne Tringali DiPiano - Malvern PA, US
Peter Kevin Mays - Philadelphia PA, US
John Ziemniak - Gwynedd Valley PA, US
International Classification:
A61K 31/58
A61P 15/00
A61P 21/00
US Classification:
514176
Abstract:
Formulations for topical or local administration of drugs directly to the breast or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the breast, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in the region to be treated with a reduction of side effects compared to those administered systemically. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion or foam.

Skin Protectant Comprising 5-Substituted And 5,5-Disubstituted 3,4-Dihydroxy-2(5H)-Furanones

View page
US Patent:
60106859, Jan 4, 2000
Filed:
Mar 8, 1999
Appl. No.:
9/264659
Inventors:
John A. Ziemniak - Gwynedd Valley PA
Allen T. Hopper - Somerset NJ
Peter T. Pugliese - Reading PA
Assignee:
Oxis International, Inc. - Portland OR
International Classification:
A61K 742
A61K 700
A61K 3134
US Classification:
424 59
Abstract:
Formulations of racemic or optically active 3,4-dihydroxy-5-aryl-2(5H)-furanoncs are provided for topical administration to the skin for the inhibition and prevention of sunburn cell formation resulting from exposure to ultraviolet radiation and other sources of damage, and for the treatment of skin aging. The compounds may be formulated in combination with a sunscreen, and may be applied before, during, and/or after exposure.

5,5-Disubstituted-3,4-Dihydroxy-2(5H)-Furanones And Methods Of Use Therefor

View page
US Patent:
61368326, Oct 24, 2000
Filed:
May 19, 1999
Appl. No.:
9/314832
Inventors:
Allen T. Hopper - Somerset NJ
John A. Ziemniak - Gwynedd Valley PA
Robert E. Johnson - Collegeville PA
Assignee:
Oxis International Inc. - Portland OR
International Classification:
A61K 3142
A61K 31365
C07D40712
C07D30762
US Classification:
514376
Abstract:
The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.

Pharmaceutical Methods Of Use Of 5-Substituted And 5,5 Disubstituted-3,4-Dihydroxy-2(5H)-Furanones

View page
US Patent:
62620738, Jul 17, 2001
Filed:
Jun 2, 2000
Appl. No.:
9/587038
Inventors:
Allen T. Hopper - Somerset NJ
John A. Ziemniak - Gwynedd Valley PA
Robert E. Johnson - Collegeville PA
Assignee:
Oxis International Inc. - Portland OR
International Classification:
A61K 31365
US Classification:
514312
Abstract:
The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.

5,5-Disubstituted-3, 4-Dihydroxy-2(5H)-Furanones And Methods Of Use Therefor

View page
US Patent:
60050004, Dec 21, 1999
Filed:
Aug 20, 1997
Appl. No.:
8/915099
Inventors:
Allen T. Hopper - Somerset NJ
John A. Ziemniak - Gwynedd Valley PA
Robert E. Johnson - Collegeville PA
Assignee:
Oxis International, Inc. - Portland OR
International Classification:
C07D30762
A61K 31375
US Classification:
514473
Abstract:
The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.
Control profile
John Andrew Ziemniak from Pottstown, PA, age ~69 Get Report